• Profile
Close

Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial

JAMA Dermatology Jan 08, 2020

Worm M, Simpson EL, Thaçi D, et al. - In this randomized, double-blind, phase 3 clinical trial [The Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE)] involving 422 patients (mean [SD] age, 38.2 [14.5] years; 227 [53.8%] male), researchers tested the safety and effectiveness of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. High-responding individuals treated with dupilumab in SOLO have been rerandomized 2:1:1:1 to continue their original regimen of dupilumab, 300 mg, weekly or every 2 weeks or to receive dupilumab, 300 mg, every 4 or 8 weeks or placebo for 36 weeks. The authors discovered that continued response over time was most consistent with weekly or every 2 weeks of dupilumab administration. For both continuous and categorical endpoints, longer dosage intervals and placebo resulted in a diminution of response. There have been no new safety signals. For long-term treatment, the approved regimen of 300 mg of dupilumab every 2 weeks is suggested.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay